Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice.

OBJECTIVE: : To test clinical effectiveness and tolerability of Korean Red Ginseng augmentation (RGA) in major depressive disorder (MDD) patients with difficult-to-treat.
METHODS: Thirty six patients were enrolled in this 6 weeks, prospective, clinical trial. Rating scales were MontgomeryÅsberg Depression Rating Scale (MADRS), Patient Health Questionnaire-15, Clinical Global Impression-improvement (CGI-I), and Patient Satisfaction Score. The primary endpoint was a remission rate measured by MADRS score at the end of study (≤ 10). Clinical outcomes and tolerability were assessed at baseline, week 2, and week 6.
RESULTS: Among 36 patients, 26 patients completed the study and 28 patients had post-baseline visit data. The remission rate by MADRS score was 39.3% (11/28) and 57.1% by CGI-I scores of 1 or 2 at the end of the study. The mean change of MADRS score was significantly decreased by 44.4% from baseline to the end of study. The most frequent adverse events were headache (7/28, 25.0%) during the study.
CONCLUSION: Our study indicates the putative effectiveness and tolerability of RGA for treating MDD with difficult-to-treat in clinical practice. However, adequately powered, randomized, controlled trials will be needed to confirm these results.

INTRODUCTION

A number of antidepressants have been developed and used to treat patients with major depressive disorders (MDD), but until now, the treatment of MDD has not been shown to be satisfactory with antidepressant treatment [1]. Indeed antidepressant monotherapy is a gold standard for MDD treatment, however, approximately 30−60% of MDD patients do not respond to antidepressant monotherapy in real practice [2-4].

According to the results from a recent large practical trial of MDD, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, the remission rate of MDD was 30% after the first drug treatment, 17% after the second level treatment, 14% after the third level treatment, and 13% after the fourth level treatment; and the cumulative remission rate following treatment for one year was only 70% [5]. Therefore, recent treatment guidelines for MDD includes switching to different antidepressant, combination of two or more antidepressants, or augmentation of psychotropics (i.g., thyroid hormone, lithium, tryptophan, psychostimulant, buspirone, atypical antipsychotics) as next level treatment option upon failure to current treatments [6,7].

Interestingly, augmentation of aripiprazole which is one of atypical antipsychotic for treating psychotic disorders has been widely utilized for MDD patients with the extended understanding of the action mechanism of the drug today [8,9]. When it comes to Red Ginseng (RG), it contains a large amount of saponins, and ginsenosides which are Rg1, Rg2, and Rg3 as one of these saponins. RG has known to regulate oxidative stress, apoptotic responses, and pro-inflammatory mediators, which are considered etiological perspectives for development of MDD [10]. RG has also many other promising neuropsycho-pharmacological effects on development and treatment for MDD including activating BDNF signaling pathway and up-regulation of hippocampal neurogenesis, promotion of the neurite outgrowth via ERK and AKT dependent signaling pathways [11,12], modulation of 5-HT2A receptors [13], increasing hippocampal 5-HT level [14], modulation of dopaminergic/noradrenergic neuron by protection of inflammatory reaction [15], inhibition of microglial cell, regulation of HPA axis [16], and enhancement of neuronal cell survival [17] and increased expression of BDNF/CREB [18] and so on [10]. Therefore RG is known to have positive effects on improving cognitive function, regulation of mood, accelerating mental/motor function, stress relief, and recovering physical energy. Such effects of RG should be beneficial for MDD patients since those symptoms are common in MDD patients [19]. However, there has been a dearth of evidence from clinical trials till today, particularly for MDD patients with difficult-to-treat. Hence the present study was conducted to test the clinical effectiveness and tolerability of Korean RG augmentation (RGA) in difficult-to-treat MDD patients who were currently on antidepressant mono-therapy.

METHODS

The present study was a prospective, open label, 6-week study to evaluate the effectiveness and tolerability of RGA in difficult-to-treat MDD patients who were currently on antidepressant monotherapy. Effectiveness and tolerability were assessed at baseline (week 0), week 2, and week 6.

Diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorders 5th edition criteria [20]. Included subjects were on 3 or more on Clinical Global Impression-Improvement (CGI-I) score despite of current antidepressant therapy with proper dosage (based on drug label information) and duration (at least 6 weeks) along with at least one or more previous failure history to antidepressant treatment. Patients were excluded if they were pregnant or nursing. Those who have current other Axis I/II diagnoses other than MDD as well as unstable medical or neurological disorders were also excluded. Those who have any psychotic symptomatology and formal/brief psychotherapeutic treatment were excluded as well.

Clinical outcome scales were Montgomery-Åsberg Depression Rating Scale (MADRS) [21], Patient Health Questionnaire-15 (PHQ-15) [22], CGI-I [23], and Patient Satisfaction Score (PSS) [24]. The primary endpoint was the remission rate measured by MADRS score (≤ 10) at the end of study. The secondary endpoints were the response rate defined as a 50% or more reduction in the MADRS score and the mean changes of MADRS, PHQ-15, and PSS scores from baseline to the end of study.

The current antidepressant and other psychotropics at the time of enrollment were maintained throughout the study. Korean Red Ginseng extract was administrated to subjects in capsule form. Aside from ginseng extract, capsules contained ginsenosides, such as Rg1 (3.4 mg/g), Rb1 (7.25 mg/g), Rg3s (0.23 mg/g), Re (2.42 mg/g), Rc (2.9 mg/g), Rb2 (2.75 mg/g), Rd (0.64 mg/g), Rf (1 mg/g), Rh1 (0.17 mg/g), Rg2s (0.32 mg/g), and other minor ginseno-sides. The dosage of RG was 2 g/day based on the previous study [25].

Statistical analysis was performed using NCSS 2007 and PASS 2008 (NCSS LLC, Kaysville, UT, USA). The data was analyzed by modified intent-to-treat population with the last observation carried forward for end of treatment analysis. Non-parametric analyses were performed because of the small sample size. 95% confidence intervals (CI) obtained where appropriate. The descriptive statistics and Wilcoxon Signed Rank test were performed where appropriate, and statistical significance was determined at p < 0.05. Under a two-tailed alpha value of 0.05, the power of our sample to detect an effect size (d = 0.5) was 80%, which corresponds to a difference in the MADRS of approximately 9 points.

The study was approved by the Institutional Review Board at Bucheon St. Mary’s hospital and was conducted in compliance with the Declaration of Helsinki (IRB approval number. HC12HISI0102). All patients provided informed consent.

RESULTS

Among 36 patients, 26 patients completed the study and 28 patients had post-baseline visit data. Ten (27.8%) patients terminated the study early as a result of adverse events (n = 1, 2.8%), protocol violation (n = 1, 2.8%) and lost to follow up (n = 8, 22.2%). Twenty-six (72.2%) of the patients completed the full 6-week trial, 28 (77.8%) of the patients returned for at least one post follow-up visit.

The mean age of the patients was approximately 48 years and three fourths was female. One had a history of admission and approximately one in five had a family history of MDD. The baseline MADRS, CGI-S, PHQ-15 and PSS scores were 21.8, 4.2, 7.7 and 4.6, respectively. The most commonly used current antidepressant was paroxetine and followed by venlafaxine. Table 1 summarizes the clinical and demographic data of the study participants.

Table 1

Baseline characteristic of samples

Parameters	Values
Age (yr)	47.8 ± 14.4
Onset age (yr)	43.9 ± 13.7
Weight (kg)	59.7 ± 10.6
Number of previous failure to antidepressant therapy	2.5 ± 1.1
CGI-S	4.2 ± 0.6
PSS	4.7 ± 0.9
MADRS	21.6 ± 4.9
PHQ-15	6.9 ± 4.4
Sex (female)	27 (75.0)
Religion (yes)	13 (36.1)
Job	4 (11.1)
Marital status (married)	21 (58.3)
Family history	6 (16.7)
Medical comorbidity, past	28 (77.8)
Current medical comorbidity	18 (50.0)
Current antidepressants
Duloxetine	2 (5.6)
Venlafaxine	9 (25.0)
Paroxetine	15 (41.7)
Sertraline	2 (5.6)
Fluoxetine	2 (5.6)
Escitalopram	3 (8.3)
Mirtazapine	3 (8.3)

Values are presented as mean ± standard deviation or number (%).

CGI-S, Clinical Global Impression-severity; PSS, Patient Satisfaction Score; MADRS, Montgomery-Åsberg Depression Rating Scale; PHQ-15, Patient Health Questionnaire-15.

The remission rate by MADRS score was 39.3% (11/28) and 57.1% by CGI-I scores of 1 or 2 at the end of the study. The response rate by MADRS score was 42.9% (12/28) at the end of study (Table 2). The mean changes of MADRS, PSS and PHQ-15 scores was significantly improved by 44.4% (p < 0.001), 31.9% (p < 0.001) and 26.1% (p= 0.019), respectively from baseline to the end of study (Table 2).

Table 2

Clinical outcome summary during the study (n = 28)

Parameters	Baseline	Week 2	Week 6	Statistical values*	95% confidence interval**
MADRS	21.6 ± 4.9	17.1 ± 5.1	12.0 ± 6.2	Z = −4.629, p < 0.001
PSS	4.7 ± 0.9	5.8 ± 1.0	6.9 ± 1.2	Z = −4.345, p < 0.001
PHQ-15	6.9 ± 4.4	5.6 ± 3.7	5.1 ± 4.3	Z = −2.339, p= 0.019
Remission rate
MADRS		1 (3.6)	11 (39.3)		0.2213−0.5927
CGI-I (1 or 2)		3 (10.7)	16 (57.1)		0.3743−0.7497
Response rate
MADRS		1 (3.6)	12 (42.9)		0.2503−0.6257

Values are presented as mean ± standard deviation or number (%).

MADRS, Montgomery-Åsberg Depression Rating Scale; PSS, Patient Satisfaction Score; PHQ-15, Patient Health Questionnaire-15; CGI-S, Clinical Global Impression-severity.

*Comparison between Baseline and end of the study and Wilcoxon Signed Rank test. **95% CI confidence interval (with continuity correction) at the end of study.

The most frequent adverse event was headache (7/28, 25.0%) and followed by depression (6/28, 21.4%), fatigue (6/28, 21.4%) and anxiety (5/28, 17.9%) during the study. Table 3 presents the summary of AEs during the study.

Table 3

Incidence of adverse events during the study (n = 28)

Parameters	Values
Headache	7 (25)
Depression	6 (21.4)
Fatigue	6 (21.4)
Anxiety	5 (17.9)
Somnolence	3 (10.7)
Pharyngitis	1 (3.6)
Gastric discomfort	1 (3.6)
Low energy	1 (3.6)
Binge eating	1 (3.6)
Palpitation	1 (3.6)

Values are presented as number (%).

DISCUSSION

The present study showed the effectiveness and tolerability of RGA in difficult-to-treat MDD patients who were currently on antidepressant monotherapy.

The potential antidepressant-like effects of RG were continuously replicated in many basic researches and few clinical trials for depressive and related disorders. A plausible mechanism for RGA to antidepressants might be its modulation and regulation on different neurotransmitters, neuroendocrine pathways, neuronal signaling pathways, neuro-inflammatory pathways and neuroprotection process and so on [10]. In fact, stress and depression impair the expression and function of BDNF in hippocampus and prefrontal cortex, which is a critical element in synaptic plasticity [11,26]. RG restores the signaling pathways of BDNF in a positive direction in MDD patients. Rb1 has an effects of modulation on 5-HT2A receptors leading to increase of 5-HT in synapse [13]. In addition, saponin has reversing effects on chronic mild stress-induced decrease of monoamine neurotransmitters including norepinephrine, dopamine, and homovanillic acid [27]. Depression is known to have abnormal cytokine homeostasis, the activation of proinflammatory cytokines and the suppression of anti-inflammatory cytokines [28]. It was found that Rg1 stimulated nitric oxide and proinflammatory cytokines (IL-1beta, IL-6, and TNF-alpha), while Rb1 showed an antagonistic activity on them [29]. Rb1 and Rg1 also regulate the genetic expression of bcl-2 and bax, both of which have been implicated in neuronal toxicity and degeneration [29]. RG improved anhedonia, hopelessness and improved sleep disruption through the modulation levels of corticosterone, testosterone, androgen receptor, and glucocorticoid receptor [16], it was also found to counteract the rise in corticotropin-releasing factor, adrenocorticotropic hormone, and cortisol in animal model study [30]. Neuroprotective effects of RG through modulation of antioxidant signal pathways and effects of autonomic system stabilization have been also continuously found [17,31].

In the first double-blind, randomized clinical trial (n = 63) [31], RG had shown better cognitive response and stabilization of sympathetic nervous system through regulation of epinephrine and steroid, which is in line with the positive effects of GR on stress control and also findings from a remote study (improvement of anxiety, depression, fatigue and somatic symptoms proven by a decrease in cortisol/DHEA-S ratio). In addition, a recent small study [32] has also shown the clinical effects of RG on improvement of residual depressive symptoms and somatic complaints, expanding treatment option for such patients. Standardized ginseng extract has also shown significant improvement of working memory performance [33].

The main strength of the present study is that our findings are the first one to have shown a possibility of RGA as a potential alternative treatment option for difficult-to-treat MDD patients. According to the results, RGA achieved remission and response rates of approximately 39% and 43% which are in line with other trials investigating augmentation treatments [9,34]. This finding is comparable to those from STAR*D trial data; indeed, remission was only 20 to 30% at level 1 and 2 treatment step, however, it decreased to 10 to 20% at level 3 and 4 treatment step. Thus, our remission rate is approximately 20% better than that from STAR*D trial, regardless of treatment level. However, the remission and response rates were quite disappointing and lower than those reported from other augmentation trials, possibly explained by no early treatment effects of RG, pharmacological characteristics of RG, low sensitivity of rating scale to detect difference with herbal medications such as RG, and sample charac-teristics. The PSS scores was also significantly decreased indicating an easy acceptance by patients themselves, which is an intriguing finding since patient-preference for treatment is one of crucial factors for better compliance and clinical outcomes in depression [35]. In addition, somatic symptoms were also significantly improved as evidenced in decrease of PHQ-15 score, which is potentially supporting the RG effects on multiple physical complaints commonly seen in MDD patients. This is in line with the beneficial effects of RG on homeostasis of autonomic system as reported in previous studies [16,25,31]. Finally RGA was also found to be tolerable in the present study; only one patient was found to withdraw the study due to AE and all AEs were mild-to-moderate.

The present study has clear limitations. The study design was not a randomized, double blind, placebo-controlled method, which might lead to potential selection bias and could not exclude the natural improvement. The sample size was small even though the power was adequate to detect symptomatic change throughout the study; however, the possibility of false positive should be considered. The pharmacokinetics of the RG was not monitored. Finally, the follow-up period was relatively short. Hence, the period over which the effect was maintained could not be determined.

Our study indicates the putative effectiveness and tolerability of RGA for treating MDD with difficult-to-treat in routine practice. However, adequately powered, randomized, controlled trials will be needed to confirm these results.